{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.82","upperLimit":"0.95","value":"0.90"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"}],"units":"Participants"}],"description":"Sensitivity, on a per-region basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy was calculated. The 95% CI was calculated using the Wilson score method.","dispersionType":"95% Confidence Interval","groups":[{"description":"PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.\n\nGa-68 labeled PSMA-11 PET: Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.","id":"OG000","title":"Ga-68 Labeled PSMA-11 PET"}],"paramType":"NUMBER","populationDescription":"Eighty-four patients had confirmed histopathology region validation for this analysis","reportingStatus":"POSTED","timeFrame":"1 month","title":"Sensitivity on a Per-region Basis","type":"SECONDARY","unitOfMeasure":"percentage of sensitivity"}